High Tide Past Earnings Performance
Past criteria checks 0/6
High Tide's earnings have been declining at an average annual rate of -27.7%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 52.9% per year.
Key information
-27.7%
Earnings growth rate
19.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 52.9% |
| Return on equity | -26.5% |
| Net Margin | -7.2% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
High Tide's NuLeaf Naturals multicannabinoid products available for sale in Ontario
Oct 18High Tide to acquire Jimmy's Cannabis Shop BC for $5.3M
Sep 29High Tide GAAP EPS of -C$0.05, revenue of C$95.35M
Sep 14High Tide gets access to C$19M credit facility
Aug 18High Tide undertakes control of Three Kushbar locations in Alberta
Jul 28High Tide to raise C$10M in equity offering
Jul 19High tide opens first canna cabana store in British Columbia
Jul 13High Tide to acquire 9 retail cannabis stores from Choom for C$5.1M
Jul 07High Tide opens new Canna Cabana store in Sherwood Park
Jun 30'We Don't Need Legalization' - High Tide CEO Raj Grover
May 19Cannabis Retailer High Tide Reports 99% Revenue Growth For Q3 2021
Sep 22High Tide: Overlooked Canadian Cannabis Stock
Jul 01High Tide Will Continue Delivering Superior Returns
Jun 22Revenue & Expenses BreakdownBeta
How High Tide makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 498 | -36 | 99 | 0 |
| 31 Oct 23 | 488 | -39 | 101 | 0 |
| 31 Jul 23 | 469 | -63 | 104 | 0 |
| 30 Apr 23 | 440 | -61 | 101 | 0 |
| 31 Jan 23 | 403 | -68 | 97 | 0 |
| 31 Oct 22 | 357 | -72 | 91 | 0 |
| 31 Jul 22 | 302 | -22 | 82 | 0 |
| 30 Apr 22 | 255 | -21 | 75 | 0 |
| 31 Jan 22 | 215 | -25 | 65 | 0 |
| 31 Oct 21 | 181 | -34 | 54 | 0 |
| 31 Jul 21 | 152 | -32 | 42 | 0 |
| 30 Apr 21 | 128 | -27 | 33 | 0 |
| 31 Jan 21 | 108 | -19 | 28 | 0 |
| 31 Oct 20 | 83 | -6 | 23 | 0 |
| 31 Jul 20 | 70 | -20 | 28 | 0 |
| 30 Apr 20 | 54 | -28 | 28 | 0 |
| 31 Jan 20 | 40 | -26 | 29 | 0 |
| 31 Oct 19 | 31 | -26 | 29 | 0 |
| 31 Jul 19 | 22 | -15 | 22 | 0 |
| 30 Apr 19 | 16 | -12 | 17 | 0 |
| 31 Jan 19 | 11 | -9 | 12 | 0 |
| 31 Oct 18 | 9 | -5 | 7 | 0 |
| 31 Jul 18 | 9 | -1 | 5 | 0 |
| 31 Oct 17 | 10 | 0 | 4 | 0 |
| 31 Oct 16 | 8 | 1 | 3 | 0 |
Quality Earnings: HITI is currently unprofitable.
Growing Profit Margin: HITI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HITI is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.
Accelerating Growth: Unable to compare HITI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HITI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: HITI has a negative Return on Equity (-26.48%), as it is currently unprofitable.